Nature Communications (Oct 2018)
Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
- Yujing Li,
- Yunhua Liu,
- Hanchen Xu,
- Guanglong Jiang,
- Kevin Van der Jeught,
- Yuanzhang Fang,
- Zhuolong Zhou,
- Lu Zhang,
- Michael Frieden,
- Lifei Wang,
- Zhenhua Luo,
- Milan Radovich,
- Bryan P. Schneider,
- Yibin Deng,
- Yunlong Liu,
- Kun Huang,
- Bin He,
- Jin Wang,
- Xiaoming He,
- Xinna Zhang,
- Guang Ji,
- Xiongbin Lu
Affiliations
- Yujing Li
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
- Yunhua Liu
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Hanchen Xu
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
- Guanglong Jiang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Kevin Van der Jeught
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Yuanzhang Fang
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Zhuolong Zhou
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Lu Zhang
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Michael Frieden
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Lifei Wang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Zhenhua Luo
- The Liver Care Center and Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center
- Milan Radovich
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine
- Bryan P. Schneider
- Department of Medicine, Indiana University School of Medicine
- Yibin Deng
- Laboratory of Cancer Genetics, The University of Minnesota Hormel Institute
- Yunlong Liu
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Kun Huang
- Department of Medicine, Indiana University School of Medicine
- Bin He
- Biomarker Research Program Center, Houston Methodist Research Institute
- Jin Wang
- Department of Pharmacology and Chemical Biology, Baylor College of Medicine
- Xiaoming He
- Fischell Department of Bioengineering, University of Maryland
- Xinna Zhang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Guang Ji
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
- Xiongbin Lu
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-018-06811-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Heterozygous loss of chromosome 17p is a common genomic event in castration-resistant prostate cancers (CRPC). Here, the authors use CRISPR-based screen to identify RBX1 as a target gene for CRPC with 17p loss and targeting RBX1 sensitizes CRPC to the treatment of α-amanitin antibody conjugates.
